Lonza offers customers a fully integrated solution, spanning design and lead molecule generation, including Synaffix ...

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

Lonza Group said it will expand manufacturing capacity at an existing facility in Visp, Switzerland, in response to growing demand for cancer drugs known as antibody-drug conjugates and similar ...

Swiss stocks tumbled on Friday, weighed down data showing a slowdown in growth, and uncertainty about Fed interest rate cuts ...

Lonza AG (Basel, Switzerland) announced it will invest in additional bioconjugation capabilities in Visp, Switzerland. The ...

As a leading CDMO for bioconjugates, Lonza has produced over 1,000 cGMP batches for more than 70 programs since 2006. Lonza offers customers a fully integrated solution, spanning design and lead ...

In 2021, Lonza Group Ag announced its largest sale of Lonza Speciality Ingredients to Bain Capital Private Equity for US$ 4.4 ...

In this article, we are going to take a look at where Lonza Group AG (OTC:LZAGY) stands against the other tech based disruptive stocks. When it comes to investing and making massive gains on the ...

Synaffix B.V. ("Synaffix"), a Lonza company (SWX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Lonza Group said it will expand manufacturing capacity at an existing facility in Visp, Switzerland, in response to growing demand for cancer drugs known as antibody-drug conjugates and similar ...